Enforcement Report - Week of June 7, 2023
British multinational drug major GlaxoSmithKline Pharmaceuticals has sold eight to 10 tail-end brands in 2018-19 (FY19), including its Vitamin C brand Celin and anti-infective brand Septran, as it focuses on paring down the number of brands in India to about 20 over the next one year. The firm’s FY19 annual report shows that it fetched Rs 5 crore during the year from the sale of brands.
The national drug pricing regulator NPPA has fixed the retail and ceiling prices of 22 formulations used for treatment of various ailments including HIV, bacterial infections and cardiac conditions among others.
Cipla and Unitaid have inked a pact to lower the price of the first combination therapy (containing co-trimoxazole, isoniazid and vitamin B6) that prevents opportunistic infections in people living with HIV.